Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Enhertu® Demonstrated a Median Progression-Free Survival of 14.3 Months as First-Line Therapy in Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial
14+ hour, 10+ min ago (848+ words) Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). In the primary endpoint analysis, Enhertu monotherapy significantly reduced…...
Noxopharm moves lupus skin therapy toward next human trial
12+ hour, 48+ min ago (292+ words) Noxopharm has announced that its lead experimental therapy, SOF-SKN, will advance to an extension clinical study in patients with cutaneous lupus erythematosus, a painful and disfiguring skin condition for which no targeted treatment currently exists. The Sydney-based company said the…...
Otsuka Arm's Lung Cancer Drug Plus Chemotherapy Trial Shows Six-Month Median PFS Benefit
12+ hour, 39+ min ago (41+ words) marketscreener.com Otsuka Holdings Co., Ltd. Otsuka Arm's Lung Cancer Drug Plus Chemotherapy Trial Shows Six-Month Median PFS Benefit Published on 09/14/2026 at 01:08 am EDT...
The eastward shift in the biotech world: Why India and China could lead the next wave
16+ hour, 47+ min ago (747+ words) China’s advantage is scale across discovery and development, and India in cost-efficiency and innovation footprint. For decades, the global biotechnology map was largely defined by a handful of established centres in the United States, and Europe. Boston, the Bay Area,…...
TAGRISSO?? (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial
13+ hour, 25+ min ago (605+ words) Longest survival data ever reported in a global Phase III trial in this setting New data reinforce TAGRISSO as the standard of care and backbone therapy in EGFRm lung cancer across stages These results were presented today during the Presidential…...
Lung cancer results boost GSK’s plan to rebuild oncology business
18+ hour, 46+ min ago (58+ words) The Times Lung cancer results boost GSK’s plan to rebuild oncology business The British pharma company presents more positive data for Jideytro, which could become a first-line treatment for certain lung tumours £1 for 3 months Enjoy unlimited access to all articles....
Servier Partnering Day: Connecting Pharma, Biotech, and Academia for New Opportunities - OncoDaily
20+ hour, 53+ min ago (107+ words) Servier shared on LinkedIn: “We are excited to announce that the next edition of the Servier Partnering Day will take place in our Paris-Saclay R/D Institute on November 23rd! This unique event is designed to bring together pharma and biotech…...
Edgewise Therapeutics Jumps As EDG-7500 Data Fuels Bullish Target Hike
1+ day, 2+ hour ago (395+ words) Edgewise Therapeutics Inc. stocks have been trading up by 7.32 percent following highly positive clinical trial advancement news. What Traders Need To Know JPMorgan lifted its price target to $60 from $53 and kept an Overweight rating after updating its model following Edgewise…...
BDRX Jumps As Biodexa Advances Phase 3 eRapa Trial
1+ day, 5+ hour ago (385+ words) Biodexa Pharmaceuticals plc stocks have been trading up by 82.49 percent amid heightened optimism over its latest clinical progress What Traders Need To Know Phase 3 Serenta trial of eRapa in Familial Adenomatous Polyposis has passed halfway enrollment, with 87 of 168 patients recruited…...
Summit’s ivonescimab cuts death risk by 27% versus Keytruda in lung cancer trial (SMMT:NASDAQ)
1+ day, 23+ min ago (64+ words) Seeking Alpha nopparit/iStock via Getty Images Summit Therapeutics (SMMT) on Sunday said ivonescimab significantly extended survival compared with Merck’s (MRK) Keytruda in a late-stage lung cancer trial conducted by its partner Akeso (AKESF) in China. Ivonescimab reduced the risk…...